On February 17, 2026, Commodore Capital disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold all 2,338,287 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in the fourth quarter, an estimated $93.86 million transaction. What happened According to a filing with the Securities and Exchange Commission dated February 17, 2026, Commodore Capital sold all 2,338,287 shares of Agios Pharmaceuticals in the fourth quarter. The position’s quarter-end value decreased by $93.86 million as a r ...

Commodore Capital reported a sale of 850,000 shares of Nuvalent (NASDAQ:NUVL) in its latest SEC filing dated February 17, 2026, with the estimated transaction value at $83.81 million based on quarterly average pricing. What happened According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Commodore Capital sold 850,000 shares of Nuvalent during the fourth quarter of 2025. The estimated value of these sales was $83.81 million based on the average closing price for the period ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and m ...

Geron Corporation (NASDAQ:GERN) is one of the 13 Best American Penny Stocks to Invest In. On January 29, TD Cowen analyst Tara Bancroft reduced the firm’s price target on Geron Corporation (NASDAQ:GERN) from $4 to $3 and maintained a Buy rating on the stock. This update comes before the company’s fourth-quarter results, which the company plans to report on February 25. In other news, on January 12, Geron Corporation (NASDAQ:GERN) shared its financial guidance for 2026. The company expects RYTELO net prod ...

Core Viewpoint - The Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab for treating Osteogenesis Imperfecta [1][3]. Company Overview - Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases [2]. Allegations of the Lawsuit - The lawsuit claims that Ultragenyx misrepresented the reliability of information regarding setrusumab's effects on patients and downplayed the risks associated with the Phase III Orbit study, which ultimately failed to show statistically significant results [3]. - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [4]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [5]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Ultragenyx common stock during the class period to seek appointment as lead plaintiff, representing the interests of the class [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years [7].

Core Viewpoint - Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics announced the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, highlighting the company's strategic focus on value-generating transactions and advancements in their product pipeline [1][3]. Company Developments - Cyprium Therapeutics has transferred the development and commercialization rights of ZYCUBO to Sentynl Therapeutics, which was approved by the FDA on January 12, 2026, for treating Menkes disease [2]. - The PRV was issued following the FDA approval of ZYCUBO, and Cyprium is set to receive tiered royalties on net sales and up to $129 million in development and sales milestones from Sentynl [2]. - Cyprium is obligated to pay 20% of the PRV sale proceeds to the Eunice Kennedy Shriver National Institute of Child Health and Human Development [2]. Strategic Positioning - Fortress Biotech's Chairman emphasized the significance of the PRV sale and recent FDA approvals for their products, indicating a strong position to execute on their portfolio [3]. - Cyprium's recent achievements include the approval of ZYCUBO and the execution of the asset sale, with plans to advance AAV-ATP7A Gene Therapy for Menkes disease [3]. Company Background - Cyprium Therapeutics focuses on developing therapies for Menkes disease and related disorders, having established a partnership with the Eunice Kennedy Shriver National Institute of Child Health and Human Development for clinical development [4]. - Fortress Biotech is an innovative biopharmaceutical company with a diverse portfolio, including eight marketed products and multiple development programs across various therapeutic areas [5].

Core Viewpoint - AIM ImmunoTech Inc. is advancing its Phase 2 clinical study of Ampligen in combination with AstraZeneca's Imfinzi for treating metastatic pancreatic cancer, with promising early results and a commitment to ongoing updates [1][2][4]. Group 1: Clinical Study Details - The DURIPANC study is an exploratory, open-label trial with 18 subjects enrolled, focusing on patients with stable disease post-FOLFIRINOX [2]. - The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center, with interim progress reports planned for mid-year and year-end [2]. - The lead investigator reported continued promising results in Progression-Free Survival and Overall Survival from Phase 1, supporting the ongoing Phase 2 study [2]. Group 2: Safety and Quality of Life - There has been no significant toxicity reported, indicating a favorable safety profile for Ampligen in a post-chemotherapy setting [3]. - Subjects receiving Ampligen have consistently reported a "high quality of life" during treatment [3]. Group 3: Future Milestones - Key milestones include completing subject enrollment by July 2026, full dosing by August 2026, and evaluating primary and secondary endpoints by December 2026 and June 2027, respectively [5]. - The primary endpoint is the Clinical Benefit Rate at 6 months, while secondary endpoints include Progression-Free Survival, Overall Survival, and immunogenic efficacy [5]. Group 4: Corporate Strategy - AIM emphasizes the potential for Ampligen's approval in pancreatic cancer, viewing this research as a significant opportunity for stockholders [4]. - The company aims to advance Ampligen towards Phase 3 clinical trials, which are often associated with substantial financial opportunities in the biotech sector [4].

Core Insights - Palisade Bio, Inc. presented new translational data for PALI-2108, a targeted oral PDE4 inhibitor prodrug, at the 21st Congress of the European Crohn's and Colitis Organization (ECCO) in Stockholm, demonstrating localized target engagement and early clinical response within seven days [1][2][10] Group 1: Clinical Findings - In a Phase 1b trial involving patients with moderate-to-severe ulcerative colitis (UC), PALI-2108 achieved a 100% clinical response rate, with 40% of patients reaching clinical remission as measured by the modified Mayo Score [5][9] - The treatment resulted in significant downregulation of inflammatory and fibrosis-associated gene expression programs, including suppression of TNF-α, JAK–STAT, NF-κB, MAPK, and TGF-β pathways [5][6] - Histologic improvements were observed alongside reductions in fecal calprotectin and high-sensitivity C-reactive protein (hsCRP) levels, indicating a decrease in inflammation [5][6] Group 2: Mechanism of Action - PALI-2108 is designed for localized delivery to the terminal ileum and colon, where it is bioactivated by bacterial enzymes, allowing for targeted PDE4 inhibition at sites of inflammation while minimizing systemic exposure [7][9] - The prodrug's pharmacological activity was confirmed through RNA sequencing and pathway analyses, which showed localized suppression of inflammatory signaling networks in colonic tissue, with peripheral immune profiles remaining largely unchanged [4][6] Group 3: Safety and Tolerability - The safety profile of PALI-2108 was encouraging, with no serious adverse events reported among the 89 subjects in the study, supporting its potential as a differentiated treatment option for inflammatory bowel diseases [1][9] - The localized pharmacology of PALI-2108 aims to improve tolerability by reducing common side effects associated with systemic PDE4 inhibitors, such as diarrhea, nausea, and headache [7][8] Group 4: Future Development - Palisade Bio is advancing PALI-2108 into a Phase 2 clinical study to evaluate clinical remission, response, and pharmacodynamic biomarkers over a 12-week period, with plans for an extension phase to assess maintenance of remission [10]

Core Viewpoint - Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics announced the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, indicating strong corporate execution and potential for profitability in the near future [1][3]. Group 1: Transaction Details - Cyprium entered into a definitive asset purchase agreement to sell its PRV for gross proceeds of $205 million upon closing [1]. - The PRV was issued following the FDA approval of ZYCUBO on January 12, 2026, which was developed by Cyprium and is intended for the treatment of Menkes disease [2]. - Cyprium will receive tiered royalties on net sales of ZYCUBO and up to $129 million in development and sales milestones from Sentynl Therapeutics [2]. Group 2: Company Achievements - The approval of ZYCUBO is a significant milestone for patients with Menkes disease, showcasing Cyprium's ability to execute value-generating transactions [3]. - Fortress has received three FDA approvals in the last 15 months for its products, including Emrosi™, UNLOXCYT™, and ZYCUBO, positioning the company for potential profitability this year [3]. - Cyprium is advancing AAV-ATP7A Gene Therapy toward clinical development, which aims to provide additional treatment options for Menkes disease [3][4]. Group 3: Company Background - Cyprium Therapeutics focuses on developing therapies for Menkes disease and related copper metabolism disorders, having established a partnership with the Eunice Kennedy Shriver National Institute of Child Health and Human Development [4]. - Fortress Biotech is an innovative biopharmaceutical company with a diverse portfolio, including eight marketed prescription products and multiple development programs across various therapeutic areas [5][6].

Core Insights - The FDA's recent policy shift allows for drug approval based on one adequate and well-controlled clinical investigation plus confirmatory evidence, rather than the traditional requirement of two pivotal studies, which could significantly lower costs and accelerate the NDA submission process for Adial's lead drug candidate, AD04 [1][2][3] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for addiction and related disorders, with its lead investigational drug candidate, AD04, targeting Alcohol Use Disorder (AUD) in heavy drinking patients [5] - AD04 is a genetically targeted serotonin-3 receptor antagonist, and the company is preparing for a new Phase 3 clinical trial program, utilizing a proprietary diagnostic genetic test to identify target genotypes [5] Regulatory Impact - The FDA's modernization of evidentiary standards emphasizes trial quality and confirmatory support over the number of trials, which aligns with Adial's strategy to potentially conduct a single pivotal trial for AD04 [2][4] - Cary Claiborne, CEO of Adial, highlighted that this regulatory change could transform the company's development strategy by significantly lowering Phase 3 costs and improving capital efficiency [4] Clinical Development Strategy - Adial intends to engage closely with the FDA to align its evidentiary strategy for AD04 with current regulatory standards, which may enhance the strategic and economic profile of the asset [4][7] - The company believes that AD04 has the potential to treat other addictive disorders beyond AUD, including Opioid Use Disorder, gambling, and obesity [5]